The Conference on Cell & Gene Therapy for HIV Cure is supported by the following organizations:
amfAR, The Foundation for AIDS Research, is one of the world’s leading nonprofit organizations dedicated to the support of AIDS research, HIV prevention, treatment education, and the advocacy of sound AIDS related public policy. Since 1985, amfAR has invested more than $450 million in its programs and has awarded more than 3,300 grants to research teams worldwide.
Among many accomplishments, amfAR supported early studies that led to the development of four of the six main classes of anti-HIV drugs that allow people living with HIV/AIDS to live longer, healthier lives, and amfAR pioneered the research that led to the use of antiretroviral drugs to prevent mother-to-child transmission of HIV.
Today amfAR’s research focus is on the search for a cure for HIV/AIDS. Following the establishment of the amfAR Research Consortium on HIV Eradication (ARCHE) in 2010, amfAR launched the Countdown to a Cure for AIDS initiative. Backed by a $100 million research investment strategy, the Countdown is aimed at developing the scientific basis for a cure by 2020.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
Our portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Rocket Pharmaceuticals, Ltd is a privately-held biotechnology company focused on seeking cures for rare diseases through molecular and gene therapy. We are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach.
We have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. Ultimately, we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need.
For more information, please visit www.rocketpharma.com.